Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: A survey in the United States of America, Europe, and Asia Pacific region

Clinical Toxicology

Volumn 53, Issue 4, 2015, Pages 204-209

  Othong, Rittirak ^a,b,c   Devlin, John J ^b,c   Kazzi, Ziad N ^b,c  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Georgia Poison Center   (United States)

Author keywords

Long QT; Management; Poisoning; QTc prolongation; Torsades de pointes; Treatment

Indexed keywords

MAGNESIUM SULFATE;

ARTICLE; ASIA; AUSTRALIA; CARDIOVASCULAR RISK; DRUG INTOXICATION; ELECTROCARDIOGRAPHY; EUROPE; FEMALE; FRANCE; GERMANY; HEALTH SURVEY; HUMAN; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL TOXICOLOGIST; NEW ZEALAND; NOMOGRAM; PARAMEDICAL PERSONNEL; PHILIPPINES; PHYSICIAN; QT INTERVAL; QT PROLONGATION; ROMANIA; RUSSIAN FEDERATION; TORSADE DES POINTES; UNITED KINGDOM; UNITED STATES;

EID: 84964310671     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2015.1013547     Document Type: Article

References (16)

1. Kao LW, Furbee RB. Drug-induced q-T prolongation. Med Clin North Am 2005; 89:1125-1144.
2. Li EC, Esterly JS, Pohl S, Scott SD, McBride BF. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 2010; 30:684-701.
3. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American heart association and the American college of cardiology foundation. Circulation 2010; 121:1047-1060.
4. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force and the European society of cardiology comittee. Circulation 2006; 114:e385-484.
5. Manini AF, Stimmel B, Vlahov D. Racial susceptibility for QT prolongation in acute drug overdoses. J Electrocardiol 2014; 47:244-250.
6. Letsas KP, Tsikrikas S. Drug-induced proarrhythmia : QT interval prolongation and torsades de pointes. Hospital Chronicles 2011; 6:118-122.
7. Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 2003; 37:999-1002.
8. Chan A, Isbister GK, Kirkpatrick CMJ, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 2007; 100:609-615.
9. Isbister GK, Balit CR, Macleod D, Duffull SB. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol 2010; 30:391-395.
10. American College of Medical Toxicology National Journal Club. Am Coll Med Toxicol 2013. Available at: www.acmt.net. Accessed September 10, 2013.
11. Chiladakis J, Kalogeropoulos A, Zagkli F, Koutsogiannis N, Chouchoulis K, Alexopoulos D. Predicting torsade de pointes in acquired long QT syndrome: Optimal identification of critical QT interval prolongation. Cardiology 2012; 122:3-11.
12. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3:1003-1007.
13. Ehrlich JR. Choosing tools for QT correction. Heart Rhythm 2006; 3:1008-1009.
14. Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D. Preferred QT correction formula for the assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2010; 21:905-913.
15. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, Stern S. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392-397.
16. Deal N, Ahn J, Wang E. Focus on: Transcutaneous and transvenous cardiac pacing. ACEP News 2011. Available at: http://www.acep.org/Content.aspx?id=80813. Accessed June 29, 2014.